Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Sanofi ADR (SNYy)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Sanofi ADR historical data, for real-time data please try another search
43.00 +0.20    +0.47%
05/10 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 43.00 - 43.00
Type:  Equity
Market:  Germany
ISIN:  US80105N1054 
S/N:  662283
Sanofi ADR 43.00 +0.20 +0.47%

SNYy Financial Summary

 
A brief financial summary of Sanofi ADR as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

For the six months ended 30 June 2016, Sanofi SA (ADR) revenues decreased 4% to EUR16.24B. Net income before extraordinary items decreased 12% to EUR1.96B. Revenues reflect Pharmaceuticals segment decrease of 5% to EUR14.63B, Latin America segment decrease of 33% to EUR1.15B, Japan segment decrease of 22% to EUR850M. Net income also reflects Restructuring costs and similar items increase of 65% to EUR627M (expense).

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SNYy Income Statement

Gross margin TTM -
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014
Total Revenue 8890 9170 8868 8146
Gross Profit 6104 6129 6004 5538
Operating Income 1403 1685 1784 1246
Net Income 1023 1339 1190 777

SNYy Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014
Total Assets 97392 90720
Total Liabilities 41272 39083
Total Equity 56120 51637

SNYy Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -
 Cash  Net Change in Cash
Period Ending: Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014
Period Length: 0 Months 12 Months 0 Months 0 Months
Cash From Operating Activities 7690
Cash From Investing Activities -3460
Cash From Financing Activities -5180
Net Change in Cash -916
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SNY Comments

Write your thoughts about Sanofi SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Lagman Johann
Lagman Johann Apr 23, 2020 11:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
just want the FDA to make a decision already🤔
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email